{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:27:13Z","timestamp":1769596033677,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T00:00:00Z","timestamp":1337299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11906-012-0274-7","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T19:55:32Z","timestamp":1337284532000},"page":"304-309","source":"Crossref","is-referenced-by-count":39,"title":["Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and Hypertension"],"prefix":"10.1007","volume":"14","author":[{"given":"Isabella","family":"Sudano","sequence":"first","affiliation":[]},{"given":"Andreas J.","family":"Flammer","sequence":"additional","affiliation":[]},{"given":"Susanne","family":"Roas","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Enseleit","sequence":"additional","affiliation":[]},{"given":"Georg","family":"Noll","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,5,18]]},"reference":[{"issue":"8","key":"274_CR1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"D Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954\u20139.","journal-title":"JAMA"},{"issue":"7504","key":"274_CR2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","volume":"330","author":"J Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case\u2013control analysis. BMJ. 2005;330(7504):1366.","journal-title":"BMJ"},{"issue":"7499","key":"274_CR3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/bmj.330.7499.1059","volume":"330","author":"J Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ. 2005;330(7499):1059\u201363.","journal-title":"BMJ"},{"key":"274_CR4","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","volume":"115","author":"EM Antman","year":"2007","unstructured":"Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634\u2013142.","journal-title":"Circulation"},{"issue":"9349","key":"274_CR5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective C. Studies, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903\u201313.","journal-title":"Lancet"},{"issue":"9789","key":"274_CR6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(11)61174-4","volume":"378","author":"FJ He","year":"2011","unstructured":"He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet. 2011;378(9789):380\u20132.","journal-title":"Lancet"},{"issue":"1","key":"274_CR7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/HJH.0b013e32834000be","volume":"29","author":"S Czernichow","year":"2011","unstructured":"\u2022\u2022 Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B. C. Blood Pressure Lowering Treatment Trialists, The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29(1):4\u201316. Metaanalysis evaluating the link between increase\/reduction in blood pressure and major cardiovascular events.","journal-title":"J Hypertens"},{"issue":"4","key":"274_CR8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","volume":"121","author":"AG Johnson","year":"1994","unstructured":"Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289\u2013300.","journal-title":"Ann Intern Med"},{"issue":"4","key":"274_CR9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archinte.1993.00410040045007","volume":"153","author":"JE Pope","year":"1993","unstructured":"Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477\u201384.","journal-title":"Arch Intern Med"},{"issue":"3","key":"274_CR10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1742-7843.2006.pto_302.x","volume":"98","author":"S Hernandez-Diaz","year":"2006","unstructured":"Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98(3):266\u201374.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"13","key":"274_CR11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","volume":"296","author":"P McGettigan","year":"2006","unstructured":"McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633\u201344.","journal-title":"JAMA"},{"issue":"7553","key":"274_CR12","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302\u20138.","journal-title":"BMJ"},{"issue":"9","key":"274_CR13","doi-asserted-by":"crossref","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","volume":"8","author":"P McGettigan","year":"2011","unstructured":"McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.","journal-title":"PLoS Med"},{"issue":"3","key":"274_CR14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.108.805689","volume":"2","author":"WA Ray","year":"2009","unstructured":"Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, Garcia-Rodriguez LA. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155\u201363.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"21","key":"274_CR15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, V.S. Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520\u20138. 2 p following 1528.","journal-title":"N Engl J Med"},{"issue":"6","key":"274_CR16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.amjcard.2005.05.038","volume":"96","author":"FH Messerli","year":"2005","unstructured":"Messerli FH, Sichrovsky T. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? Am J Cardiol. 2005;96(6):872\u20133.","journal-title":"Am J Cardiol"},{"issue":"9651","key":"274_CR17","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(08)61490-7","volume":"372","author":"JA Baron","year":"2008","unstructured":"Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372(9651):1756\u201364.","journal-title":"Lancet"},{"issue":"11","key":"274_CR18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma I. Prevention with Celecoxib Study. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071\u201380.","journal-title":"N Engl J Med"},{"issue":"10","key":"274_CR19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.106.636746","volume":"114","author":"SD Solomon","year":"2006","unstructured":"Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114(10):1028\u201335.","journal-title":"Circulation"},{"key":"274_CR20","doi-asserted-by":"crossref","unstructured":"Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials, 2006. 1(7): p. e33.","DOI":"10.1371\/journal.pctr.0010033"},{"issue":"4","key":"274_CR21","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/HJH.0b013e328325d831","volume":"27","author":"H Krum","year":"2009","unstructured":"Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009;27(4):886\u201393.","journal-title":"J Hypertens"},{"issue":"4","key":"274_CR22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2008.12.014","volume":"157","author":"MC Becker","year":"2009","unstructured":"\u2022 Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Luscher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, Graham DY, Yeomans ND, Krum H, Ruschitzka F, Lincoff AM, Nissen SE. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157(4):606\u201312. A new study which results could help us choosing a correct treatment for patients with arthritis which may reduce pain without increasing cardiovascular risk.","journal-title":"Am Heart J"},{"key":"274_CR23","unstructured":"The Standard Care versus Celecoxib Outcome Trial (SCOTLSSS). . 2007."},{"issue":"Suppl 1","key":"274_CR24","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/00005344-200605001-00008","volume":"47","author":"H Krum","year":"2006","unstructured":"Krum H, Aw TJ, Liew D, Haas S. Blood pressure effects of COX-2 inhibitors. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S43\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"key":"274_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Krum, H., G. Swergold, A. Gammaitoni, P.M. Peloso, S.S. Smugar, S.P. Curtis, D.C. Brater, H. Wang, A. Kaur, L. Laine, M.R. Weir, and C.P. Cannon, Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther, 2011. Review aiming to evaluate the link between blood pressure increase and cardiovascular risk in patients taking nonsteroidal antiinflammatory drugs.","DOI":"10.1111\/j.1755-5922.2011.00283.x"},{"issue":"9549","key":"274_CR26","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","volume":"368","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771\u201381.","journal-title":"Lancet"},{"issue":"2","key":"274_CR27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archinte.165.2.161","volume":"165","author":"JR Sowers","year":"2005","unstructured":"Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib E. Rofecoxib, and I. Safety in Comorbidities Evaluation Trial, The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(2):161\u20138.","journal-title":"Arch Intern Med"},{"issue":"10","key":"274_CR28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2003.05.006","volume":"42","author":"LM Title","year":"2003","unstructured":"Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol. 2003;42(10):1747\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"274_CR29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/01.CIR.0000051361.69808.3A","volume":"107","author":"R Chenevard","year":"2003","unstructured":"Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107(3):405\u20139.","journal-title":"Circulation"},{"issue":"19","key":"274_CR30","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1161\/01.CIR.0000101683.30157.0B","volume":"108","author":"M Hermann","year":"2003","unstructured":"Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation. 2003;108(19):2308\u201311.","journal-title":"Circulation"},{"issue":"3","key":"274_CR31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/01.HYP.0000084603.93510.28","volume":"42","author":"ME Widlansky","year":"2003","unstructured":"Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney Jr JF, Morrow JD, Vita JA. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003;42(3):310\u20135.","journal-title":"Hypertension"},{"issue":"9435","key":"274_CR32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","volume":"364","author":"ME Farkouh","year":"2004","unstructured":"Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, Group TS. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364(9435):675\u201384.","journal-title":"Lancet"},{"issue":"1","key":"274_CR33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0009-9236(98)90123-0","volume":"63","author":"MD Guazzi","year":"1998","unstructured":"Guazzi MD, Campodonico J, Celeste F, Guazzi M, Santambrogio G, Rossi M, Trabattoni D, Alimento M. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther. 1998;63(1):79\u201386.","journal-title":"Clin Pharmacol Ther"},{"issue":"9118","key":"274_CR34","first-page":"1755","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet. 1998;351(9118):1755\u201362.","journal-title":"HOT Study Group. Lancet"},{"issue":"11","key":"274_CR35","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1097\/00004872-200211000-00031","volume":"20","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I, Wedel H, Group HOTS. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002;20(11):2301\u20137.","journal-title":"J Hypertens"},{"issue":"5","key":"274_CR36","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00004872-200205000-00038","volume":"20","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, Wedel H. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens. 2002;20(5):1015\u201322.","journal-title":"J Hypertens"},{"issue":"18","key":"274_CR37","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.110.956490","volume":"122","author":"I Sudano","year":"2010","unstructured":"\u2022\u2022 Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Luscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122(18):1789\u201396. First study in which the effect of chronic therapy with paracetamol on blood pressure and endothelial function in patients with coronary artery disease was prospectively assessed in a cross-over double blind placebo controlled manner.","journal-title":"Circulation"},{"issue":"6","key":"274_CR38","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3109\/10641968409039582","volume":"6","author":"JP Chalmers","year":"1984","unstructured":"Chalmers JP, West MJ, Wing LM, Bune AJ, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A. 1984;6(6):1077\u201393.","journal-title":"Clin Exp Hypertens A"},{"issue":"3","key":"274_CR39","first-page":"e372","volume":"15","author":"I Pavlicevic","year":"2008","unstructured":"Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15(3):e372\u201382.","journal-title":"Can J Clin Pharmacol"},{"issue":"5","key":"274_CR40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/0003-4819-107-5-628","volume":"107","author":"KL Radack","year":"1987","unstructured":"Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987;107(5):628\u201335.","journal-title":"Ann Intern Med"},{"issue":"3","key":"274_CR41","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/01.HYP.0000177437.07240.70","volume":"46","author":"JP Forman","year":"2005","unstructured":"Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46(3):500\u20137.","journal-title":"Hypertension"},{"issue":"4","key":"274_CR42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/archinte.167.4.394","volume":"167","author":"JP Forman","year":"2007","unstructured":"Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007;167(4):394\u20139.","journal-title":"Arch Intern Med"},{"issue":"18","key":"274_CR43","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/CIRCULATIONAHA.110.984054","volume":"122","author":"WB White","year":"2010","unstructured":"White WB, Campbell P. Blood pressure destabilization on nonsteroidal antiinflammatory agents: acetaminophen exposed? Circulation. 2010;122(18):1779\u201381.","journal-title":"Circulation"},{"issue":"1","key":"274_CR44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00045391-200501000-00008","volume":"12","author":"GG Graham","year":"2005","unstructured":"Graham GG, Scott KF. Mechanism of action of paracetamol. Am J Ther. 2005;12(1):46\u201355.","journal-title":"Am J Ther"},{"issue":"3","key":"274_CR45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0022-3565(25)31768-4","volume":"210","author":"MB Mattammal","year":"1979","unstructured":"Mattammal MB, Zenser TV, Brown WW, Herman CA, Davis BB. Mechanism of inhibition of renal prostaglandin production by acetaminophen. J Pharmacol Exp Ther. 1979;210(3):405\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"274_CR46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1096\/fj.07-8506com","volume":"22","author":"B Hinz","year":"2008","unstructured":"Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22(2):383\u201390.","journal-title":"FASEB J"},{"issue":"3\u20134","key":"274_CR47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1527-3458.2006.00250.x","volume":"12","author":"A Bertolini","year":"2006","unstructured":"Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006;12(3\u20134):250\u201375.","journal-title":"CNS Drug Rev"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-012-0274-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-012-0274-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-012-0274-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:42:42Z","timestamp":1743144162000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-012-0274-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,18]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1007\/s11906-012-0274-7","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,18]]}}}